Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

This was the stock's third consecutive day of losses.

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...

The latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.

The stock's rise snapped a three-day losing streak.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...